Lisata Therapeutics
LSTA
34 hedge funds and large institutions have $7.33M invested in Lisata Therapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
77% more call options, than puts
Call options by funds: $521K | Put options by funds: $295K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 → 34 (+2)
0.11% more ownership
Funds ownership: 0.86% → 0.97% (+0.11%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
22% less capital invested
Capital invested by funds: $9.41M → $7.33M (-$2.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$672K |
| 2 |
Two Sigma Advisers
New York
|
+$244K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$174K |
| 4 |
VF
Virtu Financial
New York
|
+$165K |
| 5 |
Two Sigma Investments
New York
|
+$165K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$240K |
| 2 |
Renaissance Technologies
New York
|
-$151K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$76.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$33K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$30K |
LSTA Hedge Fund Activity: Q4 2021 in Review
34 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2021, worth a combined $7.33M — down 22% from $9.41M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LSTA positions and 6 closed out — a net gain of 2 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Sabby Management, adding an estimated $672K. The largest seller was Susquehanna International Group, cutting an estimated $240K.
- 34 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2021, up from 32 in Q3 2021.
- Funds reported $7.33M of Lisata Therapeutics stock for Q4 2021, down 22% quarter-over-quarter.
- 8 funds opened new Lisata Therapeutics positions in Q4 2021 and 6 closed out, a net change of +2 holders.
- The largest Lisata Therapeutics buyer in Q4 2021 was Sabby Management, an estimated $672K added.
- The largest Lisata Therapeutics seller in Q4 2021 was Susquehanna International Group, an estimated $240K sold.
Based on aggregated 13F filings for Q4 2021.